M.D., MPH, Associate Professor of Medicine, Harvard Medical School, Director, Genomes2People Research Program
Dr. Green is a medical geneticist and physician-scientist who is internationally recognized for designing and conducting empirical studies in genomic medicine. He currently leads and co-leads the MedSeq and BabySeq Projects, respectively, two NIH-funded randomized trials designed to explore the medical, behavioral and economic implications of integrating genome sequencing into the medical care of adults and newborns. Other noteworthy contributions include leading the first experimental trials to disclose genetic risk of common complex disease (the REVEAL Study) and one of the first prospective studies of direct-to-consumer genetic testing services (the PGen Study). He was the lead author on the influential recommendations for managing incidental findings in clinical sequencing from the American College of Medical Genetics and Genomics, and a co-author on recommendations for managing incidental genomic findings in research biobanks.
Genomic Sequencing in Healthy Individuals
Despite a proliferation of clinical and research programs offering predispositional genomic sequencing (PGS) to ostensibly healthy adults, the outcomes of providing this information remain unclear. Randomized clinical trials can help researchers explore the responsible integration of PGS into medical care.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Historically genetic testing has been restricted to affected families due to the high cost of DNA sequencing. As costs come down we now have the capability to provide comprehensive genetic testing as part of health and prevention programs based on personal utility. This session explores the value and pitfalls of genetic testing in the healthy population.